MX388602B - Agonistas de receptor de neuropéptido s (npsr). - Google Patents

Agonistas de receptor de neuropéptido s (npsr).

Info

Publication number
MX388602B
MX388602B MX2018011177A MX2018011177A MX388602B MX 388602 B MX388602 B MX 388602B MX 2018011177 A MX2018011177 A MX 2018011177A MX 2018011177 A MX2018011177 A MX 2018011177A MX 388602 B MX388602 B MX 388602B
Authority
MX
Mexico
Prior art keywords
neuropeptide
receptor
receptor agonists
npsr
disorders
Prior art date
Application number
MX2018011177A
Other languages
English (en)
Other versions
MX2018011177A (es
Inventor
Carla Hassler
Craig Shiner
Sanju Narayanan
Scott Runyon
Original Assignee
Res Triangle Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Triangle Inst filed Critical Res Triangle Inst
Publication of MX2018011177A publication Critical patent/MX2018011177A/es
Publication of MX388602B publication Critical patent/MX388602B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan agonistas del receptor de neuropéptido S. Los agonistas NPS incluyen análogos peptidomiméticos que exhiben afinidad para y actividad en el receptor de neuropéptido S. Las moléculas pueden ser útiles en el tratamiento de trastornos, síndromes y condiciones mediadas por modulación del receptor de neuropéptido S tal como abuso de sustancia, narcolepsia, insomnio, obesidad, deterioro cognitivo, demencia, enfermedad de Alzheimer, trastorno de pánico, ansiedad generalizada, PTSD, fobias, esquizofrenia y como medicación de apoyo durante cualquier clase de programa cesación en terapia de comportamiento cognitivo, tal como adicción de fármaco, trastornos de alimentación y juegos de azar.
MX2018011177A 2016-04-04 2017-03-23 Agonistas de receptor de neuropéptido s (npsr). MX388602B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662318042P 2016-04-04 2016-04-04
PCT/US2017/023762 WO2017176461A1 (en) 2016-04-04 2017-03-23 Neuropeptide s receptor (npsr) agonists

Publications (2)

Publication Number Publication Date
MX2018011177A MX2018011177A (es) 2018-11-21
MX388602B true MX388602B (es) 2025-03-20

Family

ID=60000661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011177A MX388602B (es) 2016-04-04 2017-03-23 Agonistas de receptor de neuropéptido s (npsr).

Country Status (8)

Country Link
US (1) US11142546B2 (es)
EP (1) EP3440051B1 (es)
JP (1) JP7132125B2 (es)
CN (1) CN109153635B (es)
AU (2) AU2017246706B2 (es)
ES (1) ES2986023T3 (es)
MX (1) MX388602B (es)
WO (1) WO2017176461A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388602B (es) 2016-04-04 2025-03-20 Res Triangle Inst Agonistas de receptor de neuropéptido s (npsr).
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN108863908B (zh) * 2018-04-24 2020-06-09 宿迁联盛科技股份有限公司 一种聚合型橡胶稳定剂中间体及其制备方法
WO2022221413A2 (en) * 2021-04-13 2022-10-20 President And Fellows Of Harvard College E3 ligase binders and uses thereof
CN114712484B (zh) * 2022-03-14 2023-07-04 中山大学 一种神经肽s在制备防治晕动症药物中的应用
KR102710574B1 (ko) * 2022-03-28 2024-09-27 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3801562A (en) * 1970-11-19 1974-04-02 Rohm & Haas N-acylated peptides of amino aromatic acids and their derivatives
US3745202A (en) * 1971-03-17 1973-07-10 Us Interior Method of preparing an asymmetric membrane from a cellulose derivative
JPS6339237B2 (es) 1979-04-06 1988-08-04 Karuruberugu Baiotekunorojii Ltd As
US4339535A (en) * 1979-08-27 1982-07-13 E. R. Squibb & Sons, Inc. Process for preparing antibiotic EM 4940
WO1999038501A2 (en) * 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
WO2001052900A2 (en) * 2000-01-21 2001-07-26 Mallinckrodt Inc. Novel orthogonally protected amino acid chelators for biomedical applications
JP4771661B2 (ja) 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
TW200530157A (en) 2003-09-09 2005-09-16 Japan Tobacco Inc Dipeptidyl peptidase iv inhibitor
US7605289B2 (en) * 2005-06-17 2009-10-20 Amgen, Inc. Benzamide derivatives and uses related thereto
JP4879265B2 (ja) * 2005-07-22 2012-02-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 成長ホルモン分泌促進薬
US8957219B2 (en) 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
CN101519430A (zh) * 2009-03-20 2009-09-02 中国农业大学 一类新型保幼激素合成抑制剂－苯丙-甘-亮三肽酰胺类似物
CN101519431A (zh) * 2009-03-20 2009-09-02 中国农业大学 一类含苯丙-甘-亮三肽片段的拟肽类保幼激素合成抑制剂
MX394577B (es) 2011-10-28 2025-03-24 Neostrata Company Inc Derivados de n-acildipeptido y sus usos
WO2013086200A1 (en) 2011-12-08 2013-06-13 Research Triangle Institute Composition and method for neuropeptide s receptor (npsr) antagonists
CN104710508B (zh) * 2015-03-20 2017-11-28 兰州大学 基于内吗啡肽2和npff受体拮抗剂rf9的分叉型杂交肽及其合成方法和应用
MX388602B (es) 2016-04-04 2025-03-20 Res Triangle Inst Agonistas de receptor de neuropéptido s (npsr).

Also Published As

Publication number Publication date
CN109153635B (zh) 2022-04-08
US20190092809A1 (en) 2019-03-28
CA3018344A1 (en) 2017-10-12
EP3440051A1 (en) 2019-02-13
JP7132125B2 (ja) 2022-09-06
EP3440051B1 (en) 2024-03-20
AU2017246706B2 (en) 2020-09-17
JP2019513704A (ja) 2019-05-30
CN109153635A (zh) 2019-01-04
US11142546B2 (en) 2021-10-12
AU2020289743A1 (en) 2021-01-21
MX2018011177A (es) 2018-11-21
WO2017176461A1 (en) 2017-10-12
EP3440051A4 (en) 2019-11-27
AU2017246706A1 (en) 2018-10-04
ES2986023T3 (en) 2025-01-27

Similar Documents

Publication Publication Date Title
MX388602B (es) Agonistas de receptor de neuropéptido s (npsr).
Lock et al. Practice parameter for the assessment and treatment of children and adolescents with eating disorders
Frías et al. Comorbidity in pediatric bipolar disorder: prevalence, clinical impact, etiology and treatment
Büssing et al. Psychosocial and spiritual needs of patients with chronic diseases: validation of the Chinese version of the Spiritual Needs Questionnaire
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
PT3985002T (pt) Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EP3429605A4 (en) THERAPEUTIC FOR THE TREATMENT OF DISEASES INCLUDING THE CENTRAL NERVOUS SYSTEM
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
Baker et al. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis
EA201300133A1 (ru) Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ
EP3541790C0 (en) 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS 5-HYDROXYTRYPTAMINE (5-HT7) RECEPTOR 7 MODULATORS FOR THE TREATMENT OF PE, INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER, OR DEPRESSION
Hankey et al. Twelve-month outcomes of the AFFINITY trial of fluoxetine for functional recovery after acute stroke: AFFINITY trial steering committee on behalf of the AFFINITY trial collaboration
MX2014005183A (es) Anticuerpos anti-kdr y metodos de uso.
WO2017176460A3 (en) Neuropeptide s receptor (npsr) agonists
Guo et al. A comparison study of cognitive-behavioral therapy alone versus combination with tapered hypnotic agents in patients with chronic insomnia
Kreisel et al. 7. The role of microglia in stress-induced depression
Takeuchi The Effect of Antipsychotic Dose-reduction On Cognition
Gonçalves et al. Adult Psychiatric Comorbidities of Attention-deficit Hyperactivity Disorder Diagnosed in Childhood–Systematic Review
Vázquez-Sanabria et al. Sustained improvement of fibromyalgia syndrome after electroconvulsive therapy for intractable depression
Mijaljica Seborrhoeic dermatitis: 7 case reports
Christoforou et al. 1078–Is there evidence for a link between stress and addiction?
Stürz et al. Comments on ‘Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients’
Verbenko et al. 1839–The influence of psychoactive substances on paranoid schizophrenia
Carpenter et al. Cognitive, behavioral, and motivational therapies for substance use disorders.